Astellas Grabs License to Gene Therapy JVS-100, with Acquisition also in Cards

Astellas Pharma has sealed an exclusive worldwide licensing pact for Juventas Therapeutics’ gene therapy JVS-100, excluding China, with an option to acquire the US biotech’s lead product candidate, the two companies said on November 22. Under the agreement, Astellas was...read more